Epstein Barr Virus Articles & Analysis
9 news found
The nine human herpesviruses are herpes simplex virus 1 (HSV-1), HSV-2, varicella zoster virus (VZV), human cytomegalovirus (HCMV), human herpesvirus 6A (HHV6A), HHV6B, Epstein-Barr virus (EBV), HHV7, and Kaposi's sarcoma herpesvirus (KSHV). ...
” In addition to the oral presentation on the study of posoleucel for the treatment of BK viremia, a compassionate use report on the administration of posoleucel in a kidney transplant recipient with Epstein-Barr virus-associated leiomyosarcoma was featured in a poster at ATC (Abstract 1000). ...
ByKalaris
These recombinant antigens in immunoassays are suitable for the detection of IgG and IgM antibodies against EBV in blood samples. Epstein-Barr Virus (EBV) is one of the most prevalent human viruses, as it affects more than 90% of adults in the world. ...
For viral diseases, the lead targets of a broad and potent multi-specific antibody portfolio include HIV and SARS-CoV-2. A vaccine for Epstein-Barr virus is also in development. “The acquisition of ModeX Therapeutics significantly broadens our technology foundation and expands our product pipeline to include multi-specific ...
The company also shared progress across its virus-specific T cell (VST) programs, with its lead product, posoleucel, advancing into Phase 3 development for the prevention of infections and disease from six devastating viruses that commonly impact patients following allogeneic hematopoietic cell transplant (allo-HCT) – adenovirus (AdV), BK virus (BKV), ...
ByKalaris
Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead investigational multi-virus-specific T cell therapy, posoleucel, for the prevention of clinically significant infections and disease from six devastating viruses that commonly impact high-risk adult and pediatric patients following allogeneic hematopoietic cell ...
ByKalaris
Updated, preliminary Phase 2 data presented at EBMT Annual Meeting continue to demonstrate substantial reduction in the expected rate of clinically significant infections with posoleucel therapy 21 of 24 patients were free of clinically significant infections through the Week 14 primary endpoint AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today ...
ByKalaris
The company also provided the outlook for 2022 across its pipeline of allogeneic, off-the-shelf, virus-specific T cell (VST) therapies for immunocompromised patients, including its lead product posoleucel, an investigational VST in development for the treatment and prevention of infections and diseases caused by six common devastating viruses – adenovirus (AdV), BK ...
ByKalaris
About Posoleucel AlloVir’s lead product, posoleucel, is in late-stage clinical development as an allogeneic, off-the-shelf, multi-virus specific T-cell therapy targeting six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), ...
ByKalaris